Three Cases of Pediatric Multisystem Inflammatory Syndrome Associated with COVID-19 Due to SARS-CoV-2

Sabrina M Heidemann1,2, Bradley Tilford1,2, Christian Bauerfeld1,2

  • 1Children's Hospital of Michigan, Detroit, MI, USA.

Insights

Children can develop severe multisystem inflammatory syndrome due to COVID-19 infection. Early recognition and treatment with intravenous immunoglobulin and aspirin are crucial for recovery in pediatric patients.

Area of Science:

  • Pediatric infectious diseases
  • Cardiology
  • Critical care medicine

Background:

  • Coronavirus disease 2019 (COVID-19) typically causes mild respiratory illness in children.
  • A novel presentation of severe COVID-19 in children involves multisystem inflammation.
  • This presentation includes cardiac dysfunction and lung disease.

Observation:

  • Three pediatric cases presented with prolonged fever, conjunctivitis, rash, and lymphadenopathy.
  • Two children required mechanical ventilation, and one needed extracorporeal membrane oxygenation (ECMO).
  • All patients exhibited hyponatremia and lymphopenia, consistent with COVID-19.

Findings:

  • Multisystem inflammatory syndrome in children (MIS-C) associated with COVID-19 can lead to severe cardiorespiratory compromise.
  • Treatment with intravenous immunoglobulin and high-dose aspirin, similar to Kawasaki disease vasculitis, resulted in recovery.
  • ECMO may be necessary for cardiorespiratory support in critical cases.

Implications:

  • Early identification of MIS-C in children is vital for preventing severe outcomes.
  • Prompt treatment can improve prognosis in pediatric COVID-19 patients with systemic inflammation.
  • Understanding this severe presentation is critical for pediatric critical care and infectious disease specialists.

Related Concept Videos

Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:
2.2K
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
110